A federal jury Monday night awarded bioscience company Elysium Health $2 million in its five-year battle with its former supplier ChromaDex, rejecting all trade secrets claims brought by ChromaDex while embracing Elysium’s counter-narrative about a plot by billionaire pharmaceutical investor Phil Frost.

Elysium is to pay ChromaDex nearly $3 million for breach of contract, which is the amount of the unpaid June 2016 supply agreement that triggered the five-year battle. Jurors also agreed that current Elysium Chief Product Officer Mark Morris breached his confidentiality agreement with ChromaDex, his ex-employer.